Clinical observation of recombinant human growth hormone in the treatment of growth hormone deficiency

中国基层医药 Pub Date : 2020-03-01 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.05.008

Chun-ya Ni

{"title":"Clinical observation of recombinant human growth hormone in the treatment of growth hormone deficiency","authors":"Chun-ya Ni","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.008","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency and its effect on thyroid function. \n \n \nMethods \nFrom June 2016 to June 2018, 81 children with growth hormone deficiency in Da Jiangdong Hospital of Hangzhou were selected.The rhGH was given 1 time before bedtime, and the treatment course was 6 months.The growth and development, bone metabolism and thyroid function were compared before treatment, 3 months and 6 months after treatment. \n \n \nResults \nThe height and growth rate at 3 months after treatment [(131.76±2.28)cm, (10.40±0.87)cm/year] and at 6 months after treatment [(134.83)cm, (11.74±0.72)cm/year] were higher than those before treatment [(127.32±3.49)cm, (4.32±1.08)cm/year] (F=7.973, P=0.000, F=12.314, P=0.000), which at 6 months after treatment were higher than those 3 months after treatment (height: t=9.586, 16.405, growth rate: t=39.457, 51.448, P=0.000). There was no statistically significant difference in BMI among before treatment [(17.21±4.28)kg/m2], 3 months after treatment [(17.86±5.14)kg/m2] and 6 months after treatment [(18.01±4.35)kg/m2] (F=0.762, P=0.391). The serum levels of BGP and ALP at 3 months after treatment [(7.19±0.38)ng/mL, (129.34±8.97)U/L] and at 6 months after treatment [(7.94±0.63)ng/mL, (154.67±10.42)U/L] were higher than those before treatment [(6.38±0.57)ng/mL, (108.49±6.51)U/L] (F=8.971, P=0.000, F=15.427, P=0.000), and the levels of BGP and ALP at 6 months after treatment were higher than those 3 months after treatment (t=9.175, P=0.000, t=16.581, P=0.000). There were no statistically significant differences in serum FT3, TSH and FT4 levels before treatment, 3 months after treatment and 6 months after treatment (F=0.893, P=0.287, F=0.472, P=0.517, F=1.084, P=0213). \n \n \nConclusion \nrhGH has significant clinical effects on children with growth hormone deficiency, and has no significant effect on thyroid function, which is worthy of clinical reference. \n \n \nKey words: \nGrowth disorders; Human growth hormone; Thyroid function tests","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the clinical effect of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency and its effect on thyroid function. Methods From June 2016 to June 2018, 81 children with growth hormone deficiency in Da Jiangdong Hospital of Hangzhou were selected.The rhGH was given 1 time before bedtime, and the treatment course was 6 months.The growth and development, bone metabolism and thyroid function were compared before treatment, 3 months and 6 months after treatment. Results The height and growth rate at 3 months after treatment [(131.76±2.28)cm, (10.40±0.87)cm/year] and at 6 months after treatment [(134.83)cm, (11.74±0.72)cm/year] were higher than those before treatment [(127.32±3.49)cm, (4.32±1.08)cm/year] (F=7.973, P=0.000, F=12.314, P=0.000), which at 6 months after treatment were higher than those 3 months after treatment (height: t=9.586, 16.405, growth rate: t=39.457, 51.448, P=0.000). There was no statistically significant difference in BMI among before treatment [(17.21±4.28)kg/m2], 3 months after treatment [(17.86±5.14)kg/m2] and 6 months after treatment [(18.01±4.35)kg/m2] (F=0.762, P=0.391). The serum levels of BGP and ALP at 3 months after treatment [(7.19±0.38)ng/mL, (129.34±8.97)U/L] and at 6 months after treatment [(7.94±0.63)ng/mL, (154.67±10.42)U/L] were higher than those before treatment [(6.38±0.57)ng/mL, (108.49±6.51)U/L] (F=8.971, P=0.000, F=15.427, P=0.000), and the levels of BGP and ALP at 6 months after treatment were higher than those 3 months after treatment (t=9.175, P=0.000, t=16.581, P=0.000). There were no statistically significant differences in serum FT3, TSH and FT4 levels before treatment, 3 months after treatment and 6 months after treatment (F=0.893, P=0.287, F=0.472, P=0.517, F=1.084, P=0213). Conclusion rhGH has significant clinical effects on children with growth hormone deficiency, and has no significant effect on thyroid function, which is worthy of clinical reference. Key words: Growth disorders; Human growth hormone; Thyroid function tests

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

重组人生长激素治疗生长激素缺乏症的临床观察

目的探讨重组人生长激素（rhGH）治疗儿童生长激素缺乏症的临床疗效及其对甲状腺功能的影响。方法选择2016年6月至2018年6月杭州市大江东医院生长激素缺乏症患儿81例。rhGH于睡前给药1次，疗程6个月。比较治疗前、治疗后3个月和6个月的生长发育、骨代谢和甲状腺功能。结果治疗后3个月的身高和生长速度[（131.76±2.28）cm，（10.40±0.87）cm/年]和治疗后6个月的[（134.83）cm，治疗后6个月高于治疗后3个月（身高：t=9.586，16.405，生长速度：t=39.457，51.448，P=0.000），治疗前BMI差异无统计学意义[（17.21±4.28）kg/m2]，治疗后3个月[（17.86±5.14）kg/m2]和治疗后6个月[[（18.01±4.35）kg/m2]（F=0.762，P=0.391）（F=8.971，P=0.000，F=15.427，P=0.000），且治疗后6个月BGP和ALP水平高于治疗后3个月（t=9.175，P=0.0000，t=16.581，P=0.000。结论rhGH治疗儿童生长激素缺乏症疗效显著，对甲状腺功能无明显影响，值得临床参考。关键词：生长障碍；人体生长激素；甲状腺功能测试

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.